Drug
VX 670
VX 670: highest development phase Phase 2, developed by Vertex Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Vertex Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| VX-670 NCT06926621 | Phase 2 | Myotonic Dystrophy Type 1 (DM1) |
Latest
No recent events.
Follow VX 670 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.